Semaglutide for the management of diabesity: The real-world experience

doi:10.5662/wjm.v14.i3.91832

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2135)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-6) series.

Item

Count

PDF

HTML

1424

Figures (1-3)

172

Tables (1-6)

195

Sum=1843

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

146

Sum=208

Sep 20, 2024 (publication date) through Dec 27, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Methodology

ISSN

2222-0682

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Methodol. Sep 20, 2024; 14(3): 91832
Published online Sep 20, 2024. doi: 10.5662/wjm.v14.i3.91832

Open in New Tab Full Size Figure Download Figure

Figure 1 Illustrates the changes in glycated hemoglobin after starting semaglutide. The comparison between latest glycated hemoglobin and baseline showed a 13.7% reduction. However, in 1 year, it reached to 18.36% decline before it started rising again.

Open in New Tab Full Size Figure Download Figure

Figure 2 The weight reduction trend while using semaglutide for treatment of diabesity.

Open in New Tab Full Size Figure Download Figure

Figure 3 Displays the mean reduction in daily insulin requirement after initiating semaglutide.

Citation: Alkhalifah M, Afsar H, Shams A, Blaibel D, Chandrabalan V, Pappachan JM. Semaglutide for the management of diabesity: The real-world experience. World J Methodol 2024; 14(3): 91832
URL: https://www.wjgnet.com/2222-0682/full/v14/i3/91832.htm
DOI: https://dx.doi.org/10.5662/wjm.v14.i3.91832